<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Patients with <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> or <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> may respond to <z:chebi fb="0" ids="24017">farnesyl</z:chebi> transferase inhibitors (FTIs) with partial or complete response rates noted in about 30% of such patients </plain></SENT>
<SENT sid="1" pm="."><plain>FTIs prevent the attachment of a <z:chebi fb="23" ids="18059">lipid</z:chebi> <z:chebi fb="0" ids="24017">farnesyl</z:chebi> moiety to dependent proteins prior to their insertion into the plasma membrane and thereby prevent activity of these prenylation-dependent proteins, but their mechanism of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppression remains unknown </plain></SENT>
<SENT sid="2" pm="."><plain>Many patients receiving FTIs do experience <z:e sem="disease" ids="C0854467" disease_type="Disease or Syndrome" abbrv="">myelosuppression</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>In this work, the in vitro effects of the FTI, R115777 on <z:mpath ids='MPATH_458'>normal</z:mpath> and leukemic hematopoiesis have been examined as have its effects on <z:mpath ids='MPATH_3'>apoptosis</z:mpath> induction and cell cycle profile in both leukemic blasts and <z:mpath ids='MPATH_458'>normal</z:mpath> CD34+ cells </plain></SENT>
<SENT sid="4" pm="."><plain>R115777 was inhibitory to <z:mpath ids='MPATH_458'>normal</z:mpath> CD34+ cell proliferation and to leukemic blast cells, but did not affect long-term culture initiating cell frequency nor <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NOD</z:e>-<z:mp ids='MP_0002536'>SCID</z:mp> reconstituting capacity </plain></SENT>
<SENT sid="5" pm="."><plain>No induction of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> or cell cycle changes were noted in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> blasts </plain></SENT>
<SENT sid="6" pm="."><plain>These data suggest that <z:e sem="disease" ids="C0854467" disease_type="Disease or Syndrome" abbrv="">myelosuppression</z:e> with R115777 occurs largely at the intermediate to late progenitor stage of hematopoiesis and that cyclic use might avoid long-term marrow suppression </plain></SENT>
</text></document>